We teach you about the TAILORx clinical trial results and how this information may save many women in the future from chemotherapy.
VISIT THE BREAST CANCER SCHOOL FOR PATIENTS:
LIST OF QUESTIONS FOR YOUR DOCTORS:
Questions for your Breast Surgeon and Medical Oncologist:
*Do I qualify for an Oncotype DX genomic test?
*If so, will you order genomic testing for me?
*What if I have an "Intermediate" result?
*Do you follow the "TAILORx" trial recommendations?
*Would you order a genomic test before I see a medical oncologist?
What does the TAILORx Clinical Trial results mean to me?
On June 3rd, 2018 the results of the largest breast cancer trial reported results that help us better determine who MAY benefit or MAY NOT benefit from chemotherapy in early stage, favorable breast cancers. The results help patients and physicians better interpret the results from the genomic assay, Oncotype DX, which is commonly used in the United States. The trial concludes that most patients with an "Intermediate Recurrence Score" result may avoid chemotherapy. The results were also released for publication by the New England Journal of Medicine.
Journal Article Link:
Video Outlining the TAILORx Clinical Trial:
What is a genomic test?
These sophisticated tests are performed on a small sample of cancer tissue in appropriate patients with early stage breast cancer. Genomic tests are usually ordered after surgery when the pathology report is finalized. It measures unique aspects of the tumor to determine if a patient will benefit from chemotherapy in addition to hormonal therapy. Such “genomic assays” developed over the last decade are a dramatic advance in breast cancer care. The Oncotype DX assay by Genomic Health Inc. is the most utilized genomic assay of those available in the United States.
Who should consider a genomic test?
Patients who have small “Estrogen receptor positive” (ER+) and “HER2 receptor negative” (HER2-) tumors and no evidence of cancer in their lymph nodes may benefit from an Oncotype DX assay. The purpose of this test is to better identify people who do and do not benefit from chemotherapy. The decision to undergo chemotherapy is a complicated one. Your medical oncologist will examine multiple factors to help determine if you will benefit from chemotherapy. The NCCN Guidelines, listed in the website links below, outline in much greater detail recommendations for the use of genomic tests. An Oncotype DX test can be instrumental in this decision for many patients.
You may qualify for a Genomic Assay if…
You have early stage cancer (Stage I or II)
Your tumor is Estrogen receptor positive (ER+)
Your tumor is Her2 receptor negative (HER2-)
No cancer was found in your lymph nodes
You are willing to consider having chemotherapy
You are healthy enough to undergo chemotherapy
How is chemotherapy tailored to patients?
Genomic breast cancer tests are a leap forward in our ability to “look inside” breast cancer cells. Sophisticated breast cancer care is based upon the principle of providing maximal benefit from the least toxic therapy. Newly diagnosed breast cancer patients deserve the best information available to decide whether they need chemotherapy. Take our video lesson on “Will I Need Chemotherapy?“ (here) to understand the general concepts. Genomics is a promising and rapidly developing field.
Take Home Message:
Make sure to ask both your breast surgeon and medical oncologist if a genomic assay might play a role in your treatment decisions. For appropriate patients, these tests should be considered only one piece of the many “pieces of the puzzle” in deciding treatment decisions about chemotherapy and hormonal therapy.
Thank you so much for posting all these very informative videos. I’m better informed now and understand much better my condition. Can you please talks about types of lumpectomies and the need to remove lymph nodes
Take our Breast Cancer Surgery Course on our website. https://www.breastcancercourse.org/series/breast-cancer-surgery/ Scroll down to see the key decisions that need to be made with making surgical choices. I hope this is helpful.
Patients taking Viagra are less likely to suffer a heart attack, new research claims.
Men taking the impotence drug were found to have a lower risk of having a heart attack or dying from heart failure than those not on the medication.
The findings mean Viagra could soon be used to treat hundreds of thousands of heart failure patients and even prevent fatal heart attacks, scientists say.
Experts from the University of Manchester studied 6,000 diabetic patients who had been given Viagra to treat erectile dysfunction.
The drug relaxes muscle cells in the blood vessels supplying the penis, allowing more blood to flow there.
This increased blood flow increases the likelihood of getting an erection.
Given the increasing reports of deaths in which the use of Viagra may be implicated, clinicians need to exercise caution when advising their patients with heart
Experts believe a key ingredient in Viagra called PDE5i, which relaxes blood vessels, also prevents damage to heart cells.
Heart failure is caused by the heart failing to pump enough blood around the body at the right pressure.
It most often occurs because the heart muscle has become too weak or stiff to work properly and is usually treated with medication which supports the heart.
Despite diabetics being prone to heart problems, the study participants did not suffer as many incidents as similar patients not on the drug.